Thumbnail Image
Publication

In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633.

Ricci, Francesca
; 
Murgia, Xabier
; 
Razzetti, Roberta
; 
Pelizzi, Nicola
; 
Salomone, Fabrizio
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2017-02
Submitted date
Show all metadata
Files
Thumbnail Image
original manuscript
Adobe PDF, 147.02 KB
Thumbnail Image
figure 1
TIFF, 4.9 MB
Thumbnail Image
figure 2
TIFF, 1.25 MB
Thumbnail Image
figure 3
TIFF, 871.21 KB
Thumbnail Image
figure 4
TIFF, 632.79 KB
Other Titles
Abstract
CHF5633 is a new generation synthetic surfactant containing both SP-B and SP-C analogues developed for the treatment of respiratory distress syndrome. Here, the optimal dose and its performance in comparison to the animal-derived surfactant poractant alfa were investigated.
Citation
In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633. 2017, 81 (2):369-375 Pediatr. Res.
Affiliation
Helmholtz Institut für pharmazeutische Forschung Saarland, Universitätscampus E8.1, 66123 Saarbrücken, Germany.
Publisher
Journal
Pediatric research
URI
http://hdl.handle.net/10033/620932
DOI
10.1038/pr.2016.231
PubMed ID
27973472
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1530-0447
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Collections
publications of the research group drug delivery ([HIPS] DDEL)